{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:29:12Z","timestamp":1765758552792,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Paritaprevir\/ritonavir, ombitasvir, and dasabuvir (PrOD) with or without ribavirin shows favorable results in hepatitis C virus genotype 1 (HCV-1) patients in terms of safety and efficacy, but real-world data remain limited for those with advanced hepatic fibrosis (fibrosis 3, F3) or compensated cirrhosis (F4). A total of 941 patients treated in four hospitals (the Keelung, the Linkuo, the Chiayi and the Kaohsiung Chang Gung Memorial Hospital) through a nationwide government-funded program in Taiwan were enrolled. Patients with HCV and advanced hepatic fibrosis or compensated cirrhosis received 12 weeks of PrOD in HCV-1b and 12 or 24 weeks of PrOD plus ribavirin therapy in HCV-1a without or with cirrhosis. Advanced hepatic fibrosis or compensated cirrhosis was confirmed by either ultrasonography, fibrosis index based on 4 factors (FIB-4) test, or transient elastography\/acoustic radiation force impulse (ARFI). The safety and efficacy (sustained virologic response 12 weeks off therapy, SVR<jats:sub>12<\/jats:sub>) were evaluated. An SVR<jats:sub>12<\/jats:sub> was achieved in 887 of 898 (98.8%) patients based on the per-protocol analysis (subjects receiving \u22651 dose of any study medication and HCV RNA data available at post-treatment week 12). Child-Pugh A6 (odds ratio: 0.168; 95% confidence interval (CI): 0.043\u20130.659, <jats:italic>p<\/jats:italic>\u2009=\u20090.011) was the only significant factor of poor SVR<jats:sub>12<\/jats:sub>. Fifty-four (5.7%) patients were withdrawn early from the treatment because of hepatic decompensation (n\u2009=\u200918, 1.9%) and other adverse reactions. Multivariate analyses identified old age (odds ratio: 1.062; 95% CI: 1.008\u20131.119, <jats:italic>p<\/jats:italic>\u2009=\u20090.024) and Child-Pugh A6 (odds ratio: 4.957; 95% CI: 1.691\u201314.528, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) were significantly associated with hepatic decompensation. In conclusion, this large real-world cohort proved PrOD with or without ribavirin to be highly effective in chronic hepatitis C patients with advanced hepatic fibrosis or compensated cirrhosis. However, Child-Pugh A6 should be an exclusion criterion for first-line treatment in these patients.<\/jats:p>","DOI":"10.1038\/s41598-019-43554-3","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T15:35:48Z","timestamp":1557416148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world safety and efficacy of paritaprevir\/ritonavir\/ombitasvir plus dasabuvir\u2009\u00b1\u2009ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis"],"prefix":"10.1038","volume":"9","author":[{"given":"Chun-Hsien","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-3190","authenticated-orcid":false,"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-1967","authenticated-orcid":false,"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-Yi","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen-Yung","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-4695","authenticated-orcid":false,"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shyan","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"43554_CR1","unstructured":"World Health Organization. Hepatitis C. WHO fact sheet 164. Available at, http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en (2017)."},{"key":"43554_CR2","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 61, S45\u201357 (2014).","journal-title":"J Hepatol."},{"key":"43554_CR3","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jhep.2014.07.010","volume":"61","author":"Y Hoshida","year":"2014","unstructured":"Hoshida, Y., Fuchs, B. C., Bardeesy, N., Baumert, T. F. & Chung, R. T. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 61, S79\u201390 (2014).","journal-title":"J Hepatol."},{"key":"43554_CR4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347, 975\u2013982 (2002).","journal-title":"N Engl J Med."},{"key":"43554_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison, J. G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 361, 580\u201393 (2009).","journal-title":"N Engl J Med."},{"key":"43554_CR6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 370, 1889\u20131898 (2014).","journal-title":"N Engl J Med."},{"key":"43554_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40261-017-0565-5","volume":"37","author":"H Ahmed","year":"2017","unstructured":"Ahmed, H. et al. Safety and Efficacy of Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig. 37, 1009\u20131023 (2017).","journal-title":"Clin Drug Investig."},{"key":"43554_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"P Kwo","year":"2017","unstructured":"Kwo, P. et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection. Gastroenterology. 152, 164\u2013175 (2017).","journal-title":"Gastroenterology."},{"key":"43554_CR9","unstructured":"FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie [cited October 22, 2015]."},{"key":"43554_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/jgh.13663","volume":"32","author":"HL Chan","year":"2017","unstructured":"Chan, H. L. et al. Real-life efficacy and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. J Gastroenterol Hepatol. 32, 1230\u20131233 (2017).","journal-title":"J Gastroenterol Hepatol."},{"key":"43554_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/jgh.13912","volume":"33","author":"CH Liu","year":"2018","unstructured":"Liu, C. H. et al. Real\u2010world effectiveness and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol. 33, 710\u2013717 (2018).","journal-title":"J Gastroenterol Hepatol."},{"key":"43554_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","volume":"24","author":"ML Yu","year":"2009","unstructured":"Yu, M. L. & Chuang, W. L. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 24, 336\u2013345 (2009).","journal-title":"J Gastroenterol Hepatol."},{"key":"43554_CR13","doi-asserted-by":"publisher","first-page":"ofx028","DOI":"10.1093\/ofid\/ofx028","volume":"4","author":"CH Liu","year":"2017","unstructured":"Liu, C. H. et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect. Dis. 4, ofx028 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"43554_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/apt.13300","volume":"42","author":"LI Backus","year":"2015","unstructured":"Backus, L. I., Belperio, P. S., Shahoumian, T. A., Loomis, T. P. & Mole, L. A. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 42, 559\u2013573 (2015).","journal-title":"Veterans. Aliment Pharmacol Ther."},{"key":"43554_CR15","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad, F. et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 370, 1973\u20131982 (2014).","journal-title":"N Engl J Med."},{"key":"43554_CR16","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci, P. et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 370, 1983\u20131992 (2014).","journal-title":"N Engl J Med."},{"key":"43554_CR17","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem, S. et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 370, 1604\u20131614 (2014).","journal-title":"N Engl J Med."},{"key":"43554_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jhep.2015.10.005","volume":"64","author":"JJ Feld","year":"2016","unstructured":"Feld, J. J. et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12weeks. J. Hepatol. 64, 301\u2013307 (2016).","journal-title":"J. Hepatol."},{"key":"43554_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"GN Ioannou","year":"2016","unstructured":"Ioannou, G. N. et al. Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology. 151, 457\u2013471.e5 (2016).","journal-title":"Gastroenterology."},{"key":"43554_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/apt.13790","volume":"44","author":"R Flisiak","year":"2016","unstructured":"Flisiak, R. et al. Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir\u2009\u00b1\u2009dasabuvir\u2009\u00b1\u2009ribavirin in hepatitis C: AMBER study. Aliment. Pharmacol. Ther. 44, 946\u2013956 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"43554_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/1060028016659306","volume":"50","author":"E Chamorro-de-Vega","year":"2016","unstructured":"Chamorro-de-Vega, E. et al. Effectiveness and safety of ombitasvir-paritaprevir\/ritonavir and dasabuvir with or without ribavirin for HCV genotype 1 infection for 12 weeks under routine clinical practice. Ann. Pharmacother. 50, 901\u2013908 (2016).","journal-title":"Ann. Pharmacother."},{"key":"43554_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","volume":"66","author":"JL Calleja","year":"2017","unstructured":"Calleja, J. L. et al. Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol. 66, 1138\u20131148 (2017).","journal-title":"J Hepatol."},{"key":"43554_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/apt.13696","volume":"44","author":"LI Backus","year":"2016","unstructured":"Backus, L. I., Belperio, P. S., Shahoumian, T. A., Loomis, T. P. & Mole, L. A. Comparative effectiveness of ledipasvir\/sofosbuvir\u2009\u00b1\u2009ribavirin vs. ombitasvir\/paritaprevir\/ritonavir\/dasabuvir\u2009\u00b1\u2009ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 44, 400\u2013410 (2016).","journal-title":"Aliment Pharmacol Ther."},{"key":"43554_CR24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/liv.13550","volume":"38","author":"CM Preda","year":"2018","unstructured":"Preda, C. M. et al. Real-world efficacy and safety of ombitasvir, paritaprevir\/r\u2009+\u2009dasabuvir\u2009+\u2009ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int. 38, 602\u2013610 (2018).","journal-title":"Liver Int."},{"key":"43554_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","volume":"53","author":"D Thabut","year":"2010","unstructured":"Thabut, D. & Shah, V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 53, 976\u2013980 (2010).","journal-title":"J Hepatol."},{"key":"43554_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2011.03.002","volume":"9","author":"T Reiberger","year":"2011","unstructured":"Reiberger, T. et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 9, 602\u2013608. e1 (2011).","journal-title":"Clin Gastroenterol Hepatol."},{"key":"43554_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/liv.12861","volume":"35","author":"SH Al Marzooqi","year":"2015","unstructured":"Al Marzooqi, S. H. & Feld, J. J. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int. 35, 1923\u20131933 (2015).","journal-title":"Liver Int."},{"key":"43554_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3851\/IMP1797","volume":"22","author":"MJ Sofia","year":"2011","unstructured":"Sofia, M. J. Nucleotide prodrugs for HCV therapy. Antivir Chem Chemother. 22, 23\u201349 (2011).","journal-title":"Antivir Chem Chemother."},{"key":"43554_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","volume":"80","author":"RF Frye","year":"2006","unstructured":"Frye, R. F. et al. Liver disease selectively modulates cytochrome P450\u2013mediated metabolism. Clin Pharmacol Ther. 80, 235\u2013245 (2006).","journal-title":"Clin Pharmacol Ther."},{"key":"43554_CR30","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1128\/AAC.00399-13","volume":"57","author":"G Kalkeri","year":"2013","unstructured":"Kalkeri, G. et al. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. Antimicrob Agents Chemother. 57, 4417\u20134426 (2013).","journal-title":"Antimicrob Agents Chemother."},{"key":"43554_CR31","first-page":"148","volume":"21","author":"RT Schooley","year":"2014","unstructured":"Schooley, R. T. The fragile relationship between hepatitis C virus and its human host. Top Antivir Med. 21, 148\u2013151 (2014).","journal-title":"Top Antivir Med."},{"key":"43554_CR32","first-page":"528A","volume":"62","author":"PS Mantry","year":"2015","unstructured":"Mantry, P. S. et al. Ombitasvir\/paritaprevir\/r and dasabuvir with ribavirin for HCV genotype 1 patients with decompensated cirrhosis. Hepatology. 62, 528A\u2013529A (2015).","journal-title":"Hepatology."},{"key":"43554_CR33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.15011","volume":"48","author":"CH Liu","year":"2018","unstructured":"Liu, C. H. et al. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther. 48, 1290\u20131300 (2018).","journal-title":"Aliment Pharmacol Ther."},{"key":"43554_CR34","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at, http:\/\/www.hcvguidelines.org (2017)."},{"key":"43554_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","volume":"154","author":"CJ Liu","year":"2018","unstructured":"Liu, C. J. et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology 154, 989\u2013997 (2018).","journal-title":"Gastroenterology"},{"key":"43554_CR36","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/S0168-8278(16)00180-X","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. et al. Effect of baseline resistance associated variants on SVR with the 3D regimen with and without RBV in GT1a and GT1b-infected patients. J. Hepatol. 64, S214 (2016).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43554-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43554-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43554-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:20:19Z","timestamp":1671268819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43554-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43554"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43554-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,5,8]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7086"}}